These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 2648678

  • 1. [Interleukin-2 and cancer immunotherapy].
    Ogarkov VI, Dobkin AI, Ryzhova EV, Okulov VB, Kiselev OI.
    Vopr Onkol; 1989; 35(2):141-50. PubMed ID: 2648678
    [No Abstract] [Full Text] [Related]

  • 2. In vivo and in vitro activation of NK cytotoxicity with IL-2.
    Ibayashi Y, Tokuda Y, Saks ER, Sarna GP, Golub SH.
    Prog Clin Biol Res; 1987; 244():275-85. PubMed ID: 3498954
    [No Abstract] [Full Text] [Related]

  • 3. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
    Sondel PM, Hank JA, Kohler PC, Chen BP, Sosman J.
    Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
    [No Abstract] [Full Text] [Related]

  • 4. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
    [No Abstract] [Full Text] [Related]

  • 5. Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes.
    Salup RR, Toth JA, Hiserodt JC, Wolmark N.
    Prog Clin Biol Res; 1987; 244():39-48. PubMed ID: 2958875
    [No Abstract] [Full Text] [Related]

  • 6. [Biotherapy of cancer].
    Subirá ML, Brugarolas A.
    Rev Clin Esp; 1992 Jun; 191(2):102-8. PubMed ID: 1380172
    [No Abstract] [Full Text] [Related]

  • 7. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
    Grimm EA.
    Prog Clin Biol Res; 1987 Jun; 244():185-95. PubMed ID: 3498948
    [No Abstract] [Full Text] [Related]

  • 8. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
    Kedar E, Zeira E, Lebendiker Z, Weiss DW, Katan R, Shouval D.
    Prog Clin Biol Res; 1987 Jun; 244():59-75. PubMed ID: 3498959
    [No Abstract] [Full Text] [Related]

  • 9. Immunological effects of adoptive immunotherapy with IL-2: an overview.
    Kradin R, Yamin R, Kurnick J.
    Pathol Immunopathol Res; 1988 Jun; 7(6):434-41. PubMed ID: 3070529
    [No Abstract] [Full Text] [Related]

  • 10. [Immunotherapy of malignant diseases].
    Dorval T, Michon J, Tartour E, Fridman WH.
    Bull Cancer; 1995 Jun; 82 Suppl 2():127s-138s. PubMed ID: 7542946
    [Abstract] [Full Text] [Related]

  • 11. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
    Talmadge JE, Herberman RB.
    Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
    [No Abstract] [Full Text] [Related]

  • 12. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
    Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
    [No Abstract] [Full Text] [Related]

  • 13. [Interleukin 2].
    Voĭtenok NN.
    Ter Arkh; 1988 Apr; 60(5):42-6. PubMed ID: 3051488
    [No Abstract] [Full Text] [Related]

  • 14. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
    Rosenberg SA, Lotze MT.
    Annu Rev Immunol; 1986 Apr; 4():681-709. PubMed ID: 3518753
    [No Abstract] [Full Text] [Related]

  • 15. [Thymus hormones in the immunotherapy of malignant neoplasms (a review of the literature)].
    Nikol'skiĭ IS.
    Vrach Delo; 1988 Aug; (8):77-82. PubMed ID: 3061171
    [No Abstract] [Full Text] [Related]

  • 16. Natural killer cells and tumor immunity: 1985.
    Herberman RB.
    Year Immunol; 1986 Aug; 2():254-60. PubMed ID: 3033946
    [No Abstract] [Full Text] [Related]

  • 17. Long-term culture of LAK cells: expansion and activation signals.
    Ochoa AC, Migliori RJ, Alter BJ, Sondel PM, Simmons RL, Bach FH.
    Prog Clin Biol Res; 1987 Aug; 244():289-99. PubMed ID: 3116557
    [Abstract] [Full Text] [Related]

  • 18. Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.
    Topalian SL, Rosenberg SA.
    Important Adv Oncol; 1990 Aug; ():19-41. PubMed ID: 2182519
    [No Abstract] [Full Text] [Related]

  • 19. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA.
    Important Adv Oncol; 1986 Aug; ():55-91. PubMed ID: 3330541
    [No Abstract] [Full Text] [Related]

  • 20. [Cancer immunotherapy: new approaches].
    Blay JY, Thomachot MC, Alberti L, Bachelot T, Voorzanger-Rousselot N, Puisieux I, Odin L, Ménétrier-Caux C.
    Bull Cancer; 2000 Jan; 87(1):97-106. PubMed ID: 10673638
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.